Bendroflumethiazide

Pays: Nouvelle-Zélande

Langue: anglais

Source: Medsafe (Medicines Safety Authority)

Ingrédients actifs:

Bendroflumethiazide 2.5mg;  ;  

Disponible depuis:

Ipca Pharma (NZ) Pty Limited

DCI (Dénomination commune internationale):

Bendroflumethiazide 2.5 mg

Dosage:

2.5 mg

forme pharmaceutique:

Tablet

Composition:

Active: Bendroflumethiazide 2.5mg     Excipient: Lactose Purified talc Starch Stearic acid

Unités en paquet:

Blister pack, PVC/PVDC, 14 tablets

classe:

Prescription

Type d'ordonnance:

Prescription

Fabriqué par:

Ipca Laboratories Limited

indications thérapeutiques:

Bendrofluazide is indicated in the treatment of oedema associated with conditions such as: congestive heart failure, nephrotic syndrome and cirrhosis of the liver.

Descriptif du produit:

Package - Contents - Shelf Life: Blister pack, PVC/PVDC - 14 tablets - 24 months from date of manufacture stored at or below 25°C - Blister pack, PVC/PVDC - 28 tablets - 24 months from date of manufacture stored at or below 25°C - Bottle, plastic, HDPE - 500 tablets - 24 months from date of manufacture stored at or below 25°C - Bottle, plastic, HDPE - 1000 tablets - 24 months from date of manufacture stored at or below 25°C

Date de l'autorisation:

2006-06-28